BioMarin Pharmaceutical Inc.
1001 - 5000 employees
Founded 1997
𧏠Biotechnology
đ Pharmaceuticals
đ° Post-IPO Debt on 2020-05
Biotechnology âą Pharmaceuticals
BioMarin Pharmaceutical Inc. is a leading global biotechnology company dedicated to transforming genetic discoveries into innovative medicines. Founded in 1997, the company has developed eight marketed products that address life-threatening genetic and lysosomal storage disorders such as achondroplasia and severe hemophilia A. BioMarin is also heavily invested in research and development, with a robust pipeline of investigational medicines at various clinical trial stages. The company's mission revolves around improving patient care by leveraging scientific expertise to understand the underlying causes of these conditions. BioMarin is committed to inclusivity and patient advocacy, engaging closely with communities to enhance care and quality of life for those with rare conditions.
Director, Global Medical Engagement - Phenylketonuria (PKU) / Lysosomal Storage Disorders (LSDs)
đ June 5, 2025
đ Check your resume score for this job
Improve your chances of getting an interview by checking your resume score before you apply.
BioMarin Pharmaceutical Inc.
1001 - 5000 employees
Founded 1997
𧏠Biotechnology
đ Pharmaceuticals
đ° Post-IPO Debt on 2020-05
Biotechnology âą Pharmaceuticals
BioMarin Pharmaceutical Inc. is a leading global biotechnology company dedicated to transforming genetic discoveries into innovative medicines. Founded in 1997, the company has developed eight marketed products that address life-threatening genetic and lysosomal storage disorders such as achondroplasia and severe hemophilia A. BioMarin is also heavily invested in research and development, with a robust pipeline of investigational medicines at various clinical trial stages. The company's mission revolves around improving patient care by leveraging scientific expertise to understand the underlying causes of these conditions. BioMarin is committed to inclusivity and patient advocacy, engaging closely with communities to enhance care and quality of life for those with rare conditions.
đ Description
âą Lead development of the global medical engagement strategy for PKU/LSDs aligning with the medical plan âą Collaboration with the Medical Engagement Medical Excellence (MEMX) lead âą Development of the external medical expert engagement plan âą Accountable for execution of the medical engagement strategy among prioritized countries âą Lead development of engagement strategy as it relates to key messages from clinical trial results âą Strong collaborations with the Global Medical Engagement lead for Skeletal Conditions
đŻ Requirements
âą Advanced life science degree (e.g. doctoral degree, masterâs level degree) and at least 4 years relevant industry experience required âą PKU/LSD knowledge/experience ideal âą 4 or more years of relevant experience in clinical science, medical affairs, and/or drug development desired âą Successful people leadership experience desired, ideally of field-based team members
Apply Now
